

Contents

1 Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer	1
Jessica Wagner, Christina Leah Kline, and Wafik El-Deiry	
2 TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer	27
Lubna Danish, Daniela Stöhr, Peter Scheurich, and Nadine Pollak	
3 IAPs and Resistance to Death Receptors in Cancer	59
Laurence Dubrez and Simone Fulda	
4 Bcl-2 Proteins and TRAIL Resistance in Melanoma	79
Jürgen Eberle	
5 Regulation of Caspase-Mediated Apoptosis by the Tumor Suppressor Par-4	91
James Sledziona and Vivek M. Rangnekar	
6 Stem Cell Regulation by Death Ligands and Their Use in Cell Therapy	107
Andrea Mohr and Ralf Zwacka	
7 Atypical Immune Functions of CD95/CD95L	131
Amanda Poissonnier and Patrick Legembre	
8 TLR3 Is a Death Receptor Target in Cancer Therapy	159
Yann Estornes, Toufic Renno, and Serge Lebecque	
9 Fas/CD95, Lipid Rafts, and Cancer	187
Faustino Mollinedo and Consuelo Gajate	

10	Role of Sphingolipids in Death Receptor Signalling	229
	Fatima Bilal, Michaël Pérès, Nathalie Andrieu-Abadie, Thierry Levade, Bassam Badran, Ahmad Daher, and Bruno Ségui	
11	Posttranslational Modifications and Death Receptor Signalling	247
	Olivier Micheau	
12	System Modeling of Receptor-Induced Apoptosis	291
	François Bertaux, Dirk Drasdo, and Grégory Batt	
	Index.	309

TRAIL, Fas Ligand, TNF and TLR3 in Cancer

Micheau, O. (Ed.)

2017, XIII, 317 p. 40 illus., 35 illus. in color., Hardcover

ISBN: 978-3-319-56804-1